See the definitions below to learn more about lung cancer and understand commonly used words.
See the definitions below to learn more about lung cancer and understand commonly used words.
The ALK gene makes an ALK protein, which may be involved in signaling cell growth. Mutations of the ALK gene have been associated with certain types of cancer, including non-small cell lung cancer, sometimes referred to as NSCLC.
A type of medicine that is designed to bind to and block the activity of the ALK protein.
A type of lung cancer involving the mutation of the ALK gene.
A type of lung cancer that has spread and involves the mutation of the ALK gene.
Treatment given after surgery to help lower the risk that the cancer will come back.
The brain and the spinal cord.
In a clinical trial, new drugs, procedures, and other treatments are studied to evaluate the effects on people’s health.
An amount you have to pay for healthcare services or medicines. You pay this amount after you pay your deductible. A co-pay is usually a set dollar amount.
There are no signs of cancer left in the body following treatment. This does not mean the cancer is cured.
This is when the cancer is in stages 1, 2, or 3A. In the early stages, the tumor remains in the lungs and may not have spread to lymph nodes outside of the lungs.
A type of assessment of results that was not specifically designed to find the difference between 2 treatments in a study.
A type of assessment that looks at data that are collected after the main study period.
A measurement of time after starting treatment when half of the people in the study are alive without the disease spreading or worsening.
The middle number in a set of numbers.
Lung cancer that has spread. It’s also called advanced lung cancer, or stage 4.
A cancer that grows from inside your lungs, usually in the cells lining air passages. Not all lung cancers are classified as non-small cell. This is determined by a biopsy of tumor tissue.
The length of time from the start of treatment for a disease during which people are still alive.
A decrease in the size of the tumor(s) or the amount of cancer in the body following treatment.
Treatment that spreads through the bloodstream to affect cells all over the body.
Criteria | ALECENSA dose modification |
---|---|
ALT or AST elevation of >5X ULN with total bilirubin ≤2X ULN | Temporarily withhold until recovery to baseline or to ≤3X ULN, then resume at reduced dose. See dose reduction schedule. |
ALT or AST elevation >3X ULN with total bilirubin elevation >2X ULN in the absence of cholestasis or hemolysis | Permanently discontinue ALECENSA. |
Total bilirubin elevation >3X ULN | Temporarily withhold until recovery to baseline or to ≤1.5X ULN, then resume at reduced dose. See dose reduction schedule. |
Any grade treatment-related ILD/pneumonitis | Permanently discontinue ALECENSA. |
Grade 3 renal impairment | Temporarily withhold until serum creatinine recovers to ≤1.5X ULN, then resume at reduced dose. See dose reduction schedule. |
Grade 4 renal impairment | Permanently discontinue ALECENSA. |
Symptomatic bradycardia | Withhold ALECENSA until recovery to asymptomatic bradycardia or to a heart rate of ≥60 bpm. If contributing concomitant medication is identified and discontinued, or its dose is adjusted, resume ALECENSA at previous dose upon recovery to asymptomatic bradycardia or to a heart rate of ≥60 bpm. If no contributing concomitant medication is identified, or if contributing concomitant medications are not discontinued or dose modified, resume ALECENSA at reduced dose upon recovery to asymptomatic bradycardia or to a heart rate of ≥60 bpm. See dose reduction schedule. |
Bradycardiaa (life-threatening consequences, urgent intervention indicated) | Permanently discontinue ALECENSA if no contributing concomitant medication is identified. If contributing concomitant medication is identified and discontinued, or its dose is adjusted, resume ALECENSA at reduced dose upon recovery to asymptomatic bradycardia or to a heart rate of ≥60 bpm, with frequent monitoring as clinically indicated. Permanently discontinue ALECENSA in case of recurrence. See dose reduction schedule. |
CPK elevation of >5X ULN | Temporarily withhold until recovery to baseline or to ≤2.5X ULN, then resume at same dose. |
CPK elevation >10X ULN or second occurrence of CPK elevation of >5X ULN | Temporarily withhold until recovery to baseline or to ≤2.5X ULN, then resume at reduced dose. See dose reduction schedule. |
Hemolytic anemia | Withhold ALECENSA if hemolytic anemia is suspected. Upon resolution, resume at reduced dose or permanently discontinue. See dose reduction schedule. |
aHeart rate <60 bpm.
ALT=alanine transaminase; AST=aspartate transaminase; bpm=beats per minute; CPK=creatine phosphokinase; ILD=interstitial lung disease; ULN=upper limit of normal.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.